Biotechnology
Code Bio was founded on the belief that so much more can be done for people living with debilitating genetic diseases. Led by seasoned leaders with expertise in business, biotechnology and nanotechnology, they are advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward strategic programs that hold promise for both rare and prevalent diseases.
Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. They are driven by the potential of transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process.